Biotest Ag Pfd Shs N (BIESF) 113.4000 $BIESF

Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Systemic Lupus Erythematosus - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4wm9fh/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2013" report to their offering. 'Systemic Lupus Erythematosus - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. Scope - A snapshot of the global therapeutic scenario for Systemic Lupus Erythematosus. - A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Systemic Lupus Erythematosus pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Amgen Inc. Sanofi-Aventis Eli Lilly and Company GlaxoSmithKline plc Genentech, Inc. MedImmune LLC Biotest AG Novo Nordisk A/S Pfizer Inc. Rigel Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited UCB Group Hadasit Medical Research Services & Development Ltd Merck KGaA 4SC AG Hollis-Eden Pharmaceuticals, Inc. IMMUNOMEDICS, INC Idera Pharmaceuticals, Inc. Karo Bio Portola Pharmaceuticals, Inc. Dynavax Technologies Corporation Hansa Medical AB and many more... For more information visit http://www.researchandmarkets.com/research/4w...emic_lupus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Pneumonia - Pipeline Review, H2 2013 Features Top Players Profiled
M2 - Tue Sep 03, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rzgnns/pneumonia) has announced the addition of the "Pneumonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Pneumonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pneumonia. Pneumonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Pneumonia. - A review of the Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pneumonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some of the Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 APEPTICO Forschung und Entwicklung GmbH Aridis Pharmaceuticals LLC aRigen Pharmaceuticals, Inc. AstraZeneca PLC Basilea Pharmaceutica Ltd. Bayer AG Biotest AG Cubist Pharmaceuticals, Inc. Durata Therapeutics Inc. Flamel Technologies S.A. KYORIN Pharmaceutical Co., Ltd. KaloBios Pharmaceuticals, Inc. LTT Bio-Pharma Co., Ltd. Mucosis B.V. Paratek Pharmaceuticals, Inc. Pulmotect, Inc. Rib-X Pharmaceuticals, Inc. Sanofi-Aventis Savara, Inc. TaiGen Biotechnology Co., Ltd. Tetraphase Pharmaceuticals Inc. Toyama Chemical Co. Ltd Trius Therapeutics, Inc. Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/rzgnns/pneumonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report: 2013 Profiles 27 Players including Key and Niche Players
M2 - Tue Sep 03, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjhhwq/intravenous#summary) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 27 companies including many key and niche players such as: - Baxter International Inc. - Beijing Tiantan Biological Products Co. Ltd. - Bharat Serums and Vaccines Ltd. - Biotest AG - China Biologic Products Inc. - Guizhou Taibang Biological Products Co. Ltd. - CSL Limited - CSL Behring - Grifols S.A - Huanlan Biological Engineering Inc. - Kedrion S.p.A. - LFB Group - Octapharma AG - OMRIX Biopharmaceuticals Ltd. - Shanghai RAAS Blood Products Co. Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered: Normal 0 false false false MicrosoftInternetExplorer4 I. Introduction, Methodology & Product Definitions Ii. Executive Summary 1. Industry Overview 2. Plasma Proteins - An Overview 3. Immunoglobulins - An Overview 4. Therapy Overview 5. Regulatory Approvals 6. Product Innovations/Introductions 7. Recent Industry Activity 8. Focus On Select Players 9. Global Market Perspective Iii. Market Iv. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/hj...us#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Rheumatoid Arthritis Report - Drug Pipeline Review
M2 - Tue Sep 03, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xw6rsc/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2013" report to their offering. 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Scope - A snapshot of the global therapeutic scenario for Rheumatoid Arthritis. - A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Featured - Alcon, Inc. - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Amgen Inc. - Antares Pharma, Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Inovio Biomedical Corporation - MedImmune LLC - Isis Pharmaceuticals, Inc. - Biotest AG - Merck & Co., Inc. - Santen Pharmaceutical Co., Ltd. - Ablynx - Emergent BioSolutions Inc. - Novo Nordisk A/S - Infinity Pharmaceuticals, Inc. - Albany Molecular Research, Inc. - Plexxikon Inc. - ViaCord - arGentis Pharmaceuticals, LLC - Reliance Life Sciences Pvt. Ltd. - MediGene AG For more information visit http://www.researchandmarkets.com/research/xw6rsc/rheumatoid

Prostate Cancer - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tsvj5b/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Prostate Cancer. - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH Celsion Corporation Amgen Inc. Sanofi-Aventis Adherex Technologies Inc. AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Genentech, Inc. Inovio Biomedical Corporation Bavarian Nordic A/S Isis Pharmaceuticals, Inc. Biotest AG GenVec, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc and many more... For more information visit http://www.researchandmarkets.com/research/ts...ate_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq...epatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

First Patient Treated with Civacir® after Hepatitis C Induced Liver Transplantation in Biotest's Phase III Clinical Trial
PR Newswire - Wed Aug 07, 9:18AM CDT
Biotest AG has achieved another milestone in the development of intravenous hyperimmune globulins. After treatment with virostatics over several weeks, the first patient underwent liver transplantation and subsequently was treated with the Civacir in the Phase III clinical trial. Civacir, a 10 % hepatitis C hyperimmune globulin developed and produced at Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, is being used in a clinical trial in North America in patients undergoing liver transplantation as a consequence of Hepatitis C infection.

insPIred(TM) - Biotest Pharmaceuticals Launches Program for Primary Immunodeficiency (PI) Community
PR Newswire - Thu Jun 27, 2:00PM CDT
Biotest Pharmaceuticals Corporation ("BPC" , a wholly owned US subsidiary of Biotest AG, (Dreieich Germany), announced the launch of insPIred(TM), a comprehensive patient education, resource and support program for the PI community. The inspiration for the program was sparked by the passion and commitment of the Primary Immunodeficiency (PI) community. BPC unveiled the program during the Immune Deficiency Foundation's (IDF) Biannual meeting being held in Baltimore, Maryland.

The Global Plasma Market to Grow At A CAGR Of 10.31 Percent over the Period 2012-2016
M2 - Thu Apr 11, 12:19PM CDT
Research and Markets has announced the addition of the "Global Plasma Market 2012-2016" report to their offering. One of the key factors contributing to this market growth is the increase in the aging population. The Global Plasma market has also been witnessing the trend of increasing market consolidation. However, stringent regulations could pose a challenge to the growth of this market. Key vendors dominating this space CSL Behring LLC, Baxter International Inc., Grifols S.A., and Octapharma AG Other vendors mentioned in the report are Kedrion S.p.A., Biotest AG, Sanguine Corp., Cangene bioPharma Inc., Haemacure Corp., Kamada Inc., Omrix Biopharmaceuticals Inc., Vivostat A/S, Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Inc., Novo Nordisk A/S, sanofi S.A., China Biologic Products Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Ltd., and LFB Group. Commenting on the report, an analyst from TechNavio's Healthcare team said: ''Over the years, the Global Plasma marke

Biotest Pharmaceuticals Announces First Commercial Sales of BIVIGAM(TM)
PR Newswire - Mon Feb 04, 9:00AM CST
Biotest Pharmaceuticals Corporation (BPC) a wholly owned U.S. subsidiary of Biotest AG, is pleased to announce the first commercial sales and successful shipments of BIVIGAM(TM) [Immune Globulin Intravenous (Human), 10% Liquid] into the pharmaceutical distribution channel for use by physicians, pharmacists and hospitals throughout the United States. The product is now available on a regular basis for patients with Primary Humoral Immunodeficiency (PI).

BIVIGAM(TM) [Immune Globulin Intravenous (Human), 10% Liquid] is the First New IVIG Product Approved with a Validated and FDA Approved Thrombin Generation Assay (TGA) Test
PR Newswire - Thu Jan 31, 3:44PM CST
Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM(TM), its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI). BIVIGAM is the first new intravenous immune globulin (IVIG) to be approved by the FDA with a validated assay for measuring potential thrombogenic activity. Thrombin generation tests are utilized to detect procoagulant activity. BPC plans to begin shipments of the product shortly.

Blood Cancer - Pipeline Review, H2 2012 Report Features Players such as Boehringer Ingelheim GmbH and Amgen Inc.
M2 - Thu Jan 17, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j8jnc/blood_cancer) has announced the addition of Global Markets Direct's new report "Blood Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Blood Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Cancer. Blood Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Blood Ca

Biotest Pharmaceuticals Announces Strategic Long-Term Manufacturing, Supply and License Agreement
PR Newswire - Thu Jan 10, 3:30PM CST
Biotest Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of Biotest AG (Dreieich, Germany), today announced it has entered into a strategic long-term manufacturing, supply, and license agreement with ADMA Biologics, Inc. (ADMA).

FDA Approves Biotest's BIVIGAM(TM), an Intravenous Immune Globulin (Human), 10% liquid
PR Newswire - Thu Dec 20, 10:30AM CST
Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for BIVIGAM(TM) for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA). BIVIGAM is the first polyspecific intravenous immune globulin manufactured in the U.S. by Biotest Pharmaceuticals Corporation (BPC) at its Boca Raton, Florida facility. This product is being produced for patients in the United States, and the company plans to begin commercial shipments shortly.